

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

DONALD JACKSON, ET AL

PATENT NO: 7153678

FILED: 12/20/2001

FOR: HUMAN PHOPHATASE RET31, AND VARIANTS THEREOF

Certificate of Corrections Branch Commissioner for Patents PO BOX 1450 Alexandria. VA 22313-1450

# REQUEST FOR CERTIFICATE OF CORRECTION OF PATENT FOR PTO MISTAKE (37 C.F.R.§1.322(a))

Sir:

Attached, in duplicate, is Form PTO-1050, with at least one copy being suitable for printing. We would like to direct your attention to the following errors:

### (75) Inventors: Remove John N. Feder and Thomas C. Nelson

See Applicant's May 31, 2005 Request to Correct Inventorship under §1.48(a) (1) deleting John N. Feder and Thomas C. Nelson as inventors on this case.

We believe this error occurred through the fault of the USPTO, for which correction is sought under 37 CFR 1.322.

#### Column 530

Claim 17, line 49 - add "and" immediately prior to "at amino acid residue 584"

line 56 - add "is alanine" after "acid residue 302"

See Examiner's Amendment in the Notice of Allowance mailed March 17, 2005.

Certificate

MAR 1 5 2007

Of Correction

We believe this error occurred through the fault of the USPTO, for which correction is sought under 37 CFR 1.322.

#### Column 531

Claim 25, line 22 - add "of a member of the group consisting of" after "complementary sequence"

See Examiner's Amendment in the Notice of Allowance mailed March 17, 2005. Examiner dropped Applicant's language in the Amendment.

We believe this error occurred through the fault of the USPTO, for which correction is sought under 37 CFR 1.322.

#### Column 532

Claim 27, line 15 - substitute "substitue" with "substitute"

line 16 - substitute "substitue" with "substitute"

line 19 - substitute "substitue" with "substitute"

See Examiner's Amendment in the Notice of Allowance mailed March 17, 2005.

We believe this error occurred through the fault of the USPTO, for which correction is sought under 37 CFR 1.322.

Claim 28, line 22, substitute "wherin" with "wherein"

line 25, substitute "substitue" with "substitute"

line 26, substitute "substitue" with "substitute"

See Examiner's Amendment in the Notice of Allowance mailed March 17, 2005.

We believe this error occurred through the fault of the USPTO, for which correction is sought under 37 CFR 1.322.

Applicants submit that these corrections present no new matter and do not require reexamination, as it is clear from the patent document itself that each of the errors is of a typographical, clerical and/or minor nature, and the correct text would be readily apparent to one skilled in the field.

D0072 NP

We believe that these errors occurred through the fault of the USPTO, so no fee is believed to be due. However, if any fee not accounted for is due in connection herewith, please charge such fee to Deposit Account No. 19-3880 of the undersigned.

The USPTO is requested to kindly contact the undersigned if deemed appropriate to expedite this request.

Please send the Certificate of Correction to the address associated with customer account number 23914.

Respectfully submitted,

Bristol-Myers Squibb Company Patent Department P.O. Box 4000 Princeton, NJ 08543-4000

Stephen C. D'Amico Agent for Applicant Reg. No. 46,652

Phone: 609-252-5289
Date: 3-12-07

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

(Also Form PTO-1050)

# UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

	2011011
PATENT NO. : 7153678	Page <u>1</u> of <u>1</u>
APPLICATION NO.: 10/029345	
ISSUE DATE : 26/DEC/2006	
INVENTOR(S) : JACKSON DONALD G., KRYSTEK JR. STANLEY FA, BOL DAVID K, FEDER JOHN N, FINGER JOSHU It is certified that an error or errors appear in the above-identified is hereby corrected as shown below:	UA N, LEE LIANA M, MCATEE C P,
(75) Inventors: Remove John N. Feder and Thomas C. Nelson	
Column 530 Claim 17, line 49 - add "and" immediately prior to "at amino acid line 56 - add "is alanine" after "acid residue 302"	residue 584"
Column 531 Claim 25, line 22 - add "of a member of the group consisting of" a	after "complementary sequence"
Column 532 Claim 27, line 15 - substitute "substitue" with "substitute" line 16 - substitute "substitute" with "substitute" line 19 - substitute "substitute" with "substitute"  Claim 28, line 22, substitute "wherin" with "wherein" line 25, substitute "substitue" with "substitute" line 26, substitute "substitue" with "substitute"	

MAILING ADDRESS OF SENDER (Please do not use customer number below):

Bristol-Myers Squibb Company Patent Department P.O. Box 4000 Princeton, NJ 08543-4000

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

## UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

Page	1	of	1	

PATENT NO.

: 7153678

**APPLICATION NO.: 10/029345** 

ISSUE DATE

: 26/DEC/2006

INVENTOR(S)

JACKSON DONALD G., KRYSTEK JR. STANLEY R., BANAS DANA, BASSOLINO DONNA

A, BOL DAVID K, FEDER JOHN N, FINGER JOSHUA N, LEE LIANA M, MCATEE C P,

It is certified that an error or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

(75) Inventors: Remove John N. Feder and Thomas C. Nelson

Claim 17, line 49 - add "and" immediately prior to "at amino acid residue 584"

line 56 - add "is alanine" after "acid residue 302"

Column 531

Claim 25, line 22 - add "of a member of the group consisting of" after "complementary sequence"

Column 532

Claim 27, line 15 - substitute "substitue" with "substitute"

line 16 - substitute "substitue" with "substitute"

line 19 - substitute "substitue" with "substitute"

Claim 28, line 22, substitute "wherin" with "wherein"

line 25, substitute "substitue" with "substitute"

line 26, substitute "substitue" with "substitute"

MAILING ADDRESS OF SENDER (Please do not use customer number below):

Bristol-Myers Squibb Company Patent Department P.O. Box 4000 Princeton, NJ 08543-4000

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.